Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON) Noortje Thielen, Bronno van der Holt, Jan J. Cornelissen, Gregor E.G. Verhoef, Titia Gussinklo, Bart J. Biemond, Simon M.G. Daenen, Wendy Deenik, Rien van Marwijk Kooy, Eefke Petersen, Willem M. Smit, Peter J.M. Valk, Gert J. Ossenkoppele, Jeroen J.W.M. Janssen European Journal of Cancer Volume 49, Issue 15, Pages 3242-3246 (October 2013) DOI: 10.1016/j.ejca.2013.06.018 Copyright © 2013 Elsevier Ltd Terms and Conditions
Fig. 1 Time from randomisation until loss of MR4.5. European Journal of Cancer 2013 49, 3242-3246DOI: (10.1016/j.ejca.2013.06.018) Copyright © 2013 Elsevier Ltd Terms and Conditions
Supplementary File 1 Successive dose levels of cytarabine and imatinib in the HOVON 51 study. European Journal of Cancer 2013 49, 3242-3246DOI: (10.1016/j.ejca.2013.06.018) Copyright © 2013 Elsevier Ltd Terms and Conditions
Supplementary File 2 Flow diagram of imatinib stop study. European Journal of Cancer 2013 49, 3242-3246DOI: (10.1016/j.ejca.2013.06.018) Copyright © 2013 Elsevier Ltd Terms and Conditions